BRPI0014464B8 - precursor de insulina humana ou seu análogo, e seu emprego - Google Patents
precursor de insulina humana ou seu análogo, e seu empregoInfo
- Publication number
- BRPI0014464B8 BRPI0014464B8 BRPI0014464A BRPI0014464A BRPI0014464B8 BR PI0014464 B8 BRPI0014464 B8 BR PI0014464B8 BR PI0014464 A BRPI0014464 A BR PI0014464A BR PI0014464 A BRPI0014464 A BR PI0014464A BR PI0014464 B8 BRPI0014464 B8 BR PI0014464B8
- Authority
- BR
- Brazil
- Prior art keywords
- chain
- insulin
- human insulin
- amino acid
- analogue
- Prior art date
Links
- 101000976075 Homo sapiens Insulin Proteins 0.000 title abstract 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title abstract 5
- 239000002243 precursor Substances 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
- 150000001413 amino acids Chemical group 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 239000004026 insulin derivative Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 abstract 1
- 108010075254 C-Peptide Proteins 0.000 abstract 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
patente de invenção: "peptídeo c para preparação aperfeiçoada de insulina e análogos de insulina". a invenção refere-se a um precursor de insulina humana ou de um análogo de insulina da fórmula (i): fus-b(1-30)-rdvp-yr~ a~(1-21); na qual fus é uma seqüência qualquer de uma fração de fusão opcionalmente disponível; b(1-30) é a cadeia b de insulina humana, y representa uma cadeia de aminoácidos, que termina com um aminoácido c terminal; n é igual a 2 até 50 e indica o comprimento da cadeia de aminoácido y; e a(1-21) é a cadeia a de insulina humana, e a cadeia a e/ou a cadeia b podem ser modificadas por troca de aminoácidos, deleções e/ou adições. a invenção referese a um dna codificador para tal. a invenção refere-se ainda à preparação e emprego de precursores e ao dna, assim como a um processo para preparação de insulina humana ou um análogo a insulina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19947456A DE19947456A1 (de) | 1999-10-02 | 1999-10-02 | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
| DE19947456.7 | 1999-10-02 | ||
| PCT/EP2000/009017 WO2001025278A1 (de) | 1999-10-02 | 2000-09-15 | C-peptid zur verbesserten herstellung von insulin und insulinanaloga |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0014464B1 BRPI0014464B1 (pt) | 2018-03-13 |
| BRPI0014464B8 true BRPI0014464B8 (pt) | 2021-05-25 |
Family
ID=7924253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0014464A BRPI0014464B8 (pt) | 1999-10-02 | 2000-09-15 | precursor de insulina humana ou seu análogo, e seu emprego |
| BR0014464-9A BR0014464A (pt) | 1999-10-02 | 2000-09-15 | Peptìdeo c para preparação aperfeiçoada de insulina e análogos de insulina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014464-9A BR0014464A (pt) | 1999-10-02 | 2000-09-15 | Peptìdeo c para preparação aperfeiçoada de insulina e análogos de insulina |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6534288B1 (pt) |
| EP (1) | EP1222207B1 (pt) |
| JP (1) | JP4681784B2 (pt) |
| KR (1) | KR100823463B1 (pt) |
| CN (1) | CN1193042C (pt) |
| AT (1) | ATE380196T1 (pt) |
| AU (1) | AU778369B2 (pt) |
| BR (2) | BRPI0014464B8 (pt) |
| CA (1) | CA2385857C (pt) |
| CY (1) | CY1107860T1 (pt) |
| DE (2) | DE19947456A1 (pt) |
| DK (1) | DK1222207T3 (pt) |
| ES (1) | ES2295054T3 (pt) |
| HK (1) | HK1049016B (pt) |
| HU (1) | HU228313B1 (pt) |
| IL (2) | IL148942A0 (pt) |
| MX (1) | MXPA02003103A (pt) |
| NO (1) | NO329975B1 (pt) |
| NZ (1) | NZ518066A (pt) |
| PL (1) | PL203195B1 (pt) |
| PT (1) | PT1222207E (pt) |
| SI (1) | SI1222207T1 (pt) |
| TW (1) | TWI265168B (pt) |
| WO (1) | WO2001025278A1 (pt) |
| ZA (1) | ZA200202520B (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US20050250676A1 (en) * | 2001-11-19 | 2005-11-10 | Aventis Pharma Deutschland Gmbh | Method of activating insulin receptor substrate-2 to stimulate insulin production |
| US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
| DE10235168A1 (de) * | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
| EP1692168B1 (en) | 2003-12-03 | 2011-07-20 | Novo Nordisk A/S | Single-chain insulin |
| CN1663960B (zh) * | 2004-03-01 | 2012-07-04 | 重庆富进生物医药有限公司 | 高效表达重组人胰岛素原及其类似物的新型c肽 |
| WO2007121318A2 (en) * | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| DE102008025007A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008025008A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| JP5695909B2 (ja) | 2008-01-09 | 2015-04-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PL2611458T3 (pl) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| MX2016008978A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol. |
| BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
| MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2025099208A1 (en) | 2023-11-10 | 2025-05-15 | Intervet International B.V. | Recombinant insulin precursor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811972B (en) * | 1980-03-27 | 1982-11-24 | Lilly Co Eli | Process for producing an insulin precursor |
| US4430266A (en) * | 1980-11-28 | 1984-02-07 | Eli Lilly And Company | Process for producing an insulin precursor |
| HRP940432B1 (en) * | 1994-08-05 | 2003-10-31 | Pliva Pharm & Chem Works | Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin |
| PT821006E (pt) * | 1996-07-26 | 2004-09-30 | Aventis Pharma Gmbh | Derivados de insulina com ligacao a zinco aumentada |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
-
1999
- 1999-10-02 DE DE19947456A patent/DE19947456A1/de not_active Withdrawn
-
2000
- 2000-09-15 KR KR1020027004275A patent/KR100823463B1/ko not_active Expired - Lifetime
- 2000-09-15 JP JP2001528218A patent/JP4681784B2/ja not_active Expired - Lifetime
- 2000-09-15 SI SI200030981T patent/SI1222207T1/sl unknown
- 2000-09-15 HU HU0202755A patent/HU228313B1/hu unknown
- 2000-09-15 DK DK00960664T patent/DK1222207T3/da active
- 2000-09-15 BR BRPI0014464A patent/BRPI0014464B8/pt unknown
- 2000-09-15 PL PL354078A patent/PL203195B1/pl unknown
- 2000-09-15 BR BR0014464-9A patent/BR0014464A/pt not_active IP Right Cessation
- 2000-09-15 AU AU72877/00A patent/AU778369B2/en not_active Expired
- 2000-09-15 CA CA2385857A patent/CA2385857C/en not_active Expired - Lifetime
- 2000-09-15 HK HK03101211.8A patent/HK1049016B/zh not_active IP Right Cessation
- 2000-09-15 ES ES00960664T patent/ES2295054T3/es not_active Expired - Lifetime
- 2000-09-15 AT AT00960664T patent/ATE380196T1/de active
- 2000-09-15 IL IL14894200A patent/IL148942A0/xx unknown
- 2000-09-15 EP EP00960664A patent/EP1222207B1/de not_active Expired - Lifetime
- 2000-09-15 MX MXPA02003103A patent/MXPA02003103A/es active IP Right Grant
- 2000-09-15 NZ NZ518066A patent/NZ518066A/en not_active IP Right Cessation
- 2000-09-15 DE DE50014830T patent/DE50014830D1/de not_active Expired - Lifetime
- 2000-09-15 WO PCT/EP2000/009017 patent/WO2001025278A1/de not_active Ceased
- 2000-09-15 CN CNB008137137A patent/CN1193042C/zh not_active Expired - Lifetime
- 2000-09-15 PT PT00960664T patent/PT1222207E/pt unknown
- 2000-09-29 TW TW089120149A patent/TWI265168B/zh not_active IP Right Cessation
- 2000-10-02 US US09/676,787 patent/US6534288B1/en not_active Expired - Lifetime
-
2002
- 2002-03-18 NO NO20021335A patent/NO329975B1/no not_active IP Right Cessation
- 2002-03-28 ZA ZA200202520A patent/ZA200202520B/xx unknown
- 2002-03-31 IL IL148942A patent/IL148942A/en active IP Right Grant
-
2008
- 2008-01-18 CY CY20081100078T patent/CY1107860T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0014464B8 (pt) | precursor de insulina humana ou seu análogo, e seu emprego | |
| BRPI9803708B8 (pt) | derivados de insulina de rápido início de ação, processo para a sua preparação, bem como precursor, preparação farmacêutica, solução injetável e uso | |
| BRPI0413276A (pt) | derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente | |
| KR100574580B1 (ko) | 정확하게 결합된 시스틴 브릿지를 갖는 인슐린 또는 인슐린유도체를 수득하는 방법 | |
| BRPI0209685B8 (pt) | derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópico | |
| BR0213377A (pt) | mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas | |
| BR9814471A (pt) | Composições insolúveis para controle de glicose sanguìnea | |
| ATE466028T1 (de) | N-terminal veränderte glp-1 abkömmlinge | |
| DE102008003566A1 (de) | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil | |
| EP2229406A2 (de) | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil | |
| KR870002165A (ko) | 인슈린유사체 및 그의 제조방법 | |
| BR9810378A (pt) | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero | |
| DE3104949C2 (de) | Verfahren zur Herstellung von Threonin↑B↑↑3↑↑0↑-Estern des Humaninsulins, demgemäß hergestellte Threonin↑B↑↑3↑↑0↑-Ester des Humaninsulins sowie Verfahren zur Herstellung von Humaninsulin unter Verwendung derartiger Threonin↑B↑↑3↑↑0↑-Ester des Humaninsulins | |
| EP1084248A2 (de) | Neue insulinanaloga mit erhöhter zinkbindung | |
| DE102008025008A1 (de) | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil | |
| DK171440B1 (da) | Fremgangsmåde til undertrykkelse af uønskede thio-reaktioner under spaltning af peptider med cyanogenbromid | |
| DE68913080T2 (de) | S-sulfonierte Calcitonin-Derivate. | |
| DE3667472D1 (de) | Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen. | |
| EP1735343A1 (de) | Verfahren zur gewinnung von insulinen durch verbesserte luftbegasung der faltung | |
| DE102008025007A1 (de) | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil | |
| EP3904373A1 (en) | Composition for converting insulin precursor into insulin enzyme and method for converting insulin precursor into insulin by using same |